Who are nicotine nasal spray's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pre-Quit Nicotine Gum, Nicotine replacement, Nicotine polacrilex lozenge, Naltrexone Tablet and Nicotine Patch, Standard Duration Combination NRT, Transdermal nicotine patch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-nasal-spray.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

nicotine nasal spray — Competitive Intelligence Brief

nicotine nasal spray (nicotine nasal spray) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic receptor agonist. Area: Smoking Cessation / Addiction Medicine.

marketed Nicotinic receptor agonist Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

nicotine nasal spray (nicotine nasal spray) — Heinrich-Heine University, Duesseldorf. Nicotine nasal spray delivers nicotine directly to nasal mucosa for rapid systemic absorption to relieve nicotine withdrawal symptoms and support smoking cessation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
nicotine nasal spray TARGET	nicotine nasal spray	Heinrich-Heine University, Duesseldorf	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine polacrilex lozenge	Nicotine polacrilex lozenge	University of Maryland, Baltimore	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Naltrexone Tablet and Nicotine Patch	Naltrexone Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Opioid antagonist + nicotine replacement therapy combination	Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine)
Standard Duration Combination NRT	Standard Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy combination	Nicotinic acetylcholine receptors
Transdermal nicotine patch	Transdermal nicotine patch	University of Pennsylvania	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic receptor agonist class)

Heinrich-Heine University, Duesseldorf · 1 drug in this class
The University of Hong Kong · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nicotine nasal spray — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-nasal-spray. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab